10:24 AM EDT, 03/16/2026 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Monday it has completed enrollment in a phase 3 trial evaluating Livmarli for the treatment of cholestatic pruritus in patients with additional rare cholestatic liver diseases.

The study is a randomized, double-blind, placebo-controlled trial assessing Livmarli in patients aged six months or older with conditions including biliary atresia, the company said.

Mirum said the study is designed to support a potential label expansion for Livmarli in additional settings of cholestatic pruritus and topline data is expected in Q4.

Price: 91.61, Change: +0.95, Percent Change: +1.05